NewAmsterdam Pharma Executive Compensation Details Released
Ticker: NAMSW · Form: DEF 14A · Filed: May 8, 2025 · CIK: 1936258
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
Related Tickers: NAMS
TL;DR
NAMS DEF 14A out: exec comp details for 2024, equity awards for PEOs & Non-PEOs.
AI Summary
NewAmsterdam Pharma Co N.V. filed a DEF 14A on May 8, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both PEO (Principal Executive Officer) and Non-PEO NEOs (Non-Principal Executive Officer Named Executive Officers), with specific data points on the change in fair value of outstanding equity awards and vesting dates.
Why It Matters
This filing provides transparency into how NewAmsterdam Pharma compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing executive compensation details, not indicating new financial distress or significant operational changes.
Key Players & Entities
- NewAmsterdam Pharma Co N.V. (company) — Filer of the DEF 14A
- 0001936258 (company) — Central Index Key for NewAmsterdam Pharma Co N.V.
- 20250508 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for which compensation is reported
- 2023-01-01 (date) — Start of prior fiscal year for comparative data
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of NewAmsterdam Pharma Co N.V.'s named executive officers for the fiscal year ending December 31, 2024.
What types of equity awards are detailed in the filing?
The filing details equity awards, including those granted to PEO (Principal Executive Officer) and Non-PEO NEOs (Non-Principal Executive Officer Named Executive Officers), and covers aspects like the change in fair value of outstanding awards and vesting dates.
When was this DEF 14A filed with the SEC?
This DEF 14A filing was made on May 8, 2025.
What is the fiscal year end for the reported compensation data?
The compensation data reported in this filing pertains to the fiscal year ending December 31, 2024.
What was the former name of NewAmsterdam Pharma Co N.V. and when did the change occur?
The former name of NewAmsterdam Pharma Co N.V. was NewAmsterdam Pharma Co B.V., and the name change occurred on July 1, 2022.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 8, 2025 regarding NewAmsterdam Pharma Co N.V. (NAMSW).